Understand the source comparison
Peptides for Cognitive Enhancement: Product Comparison
Cerebrolysin NGF/BDNF mimetic; TrkB receptor activation 30+ RCTs; Cochrane review meta-analysis 10–30mL IV daily for 10–20 days Approved in 44 countries; not FDA-approved Strongest human evidence base; requires IV administration Dihexa HGF receptor agonist; pr
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin
- NGF/BDNF mimetic; TrkB receptor activation
- 30+ RCTs; Cochrane review meta-analysis
- 10–30mL IV daily for 10–20 days
- Approved in 44 countries; not FDA-approved
- Strongest human evidence base; requires IV administration
- Dihexa
- HGF receptor agonist; promotes neurogenesis
- Rodent studies only; no human trials
- 0.5–2mg subcutaneous daily (research)
- Research-grade only; no clinical approval
- Potent preclinical data; human safety unknown
- P21
- CNTF derivative; acetylcholine modulation
- Animal models; no human RCTs
- 1mg subcutaneous 2–3×/week (research)
- Research-grade only
- Promising rodent memory data; extrapolation to humans uncertain
- Semax
- ACTH fragment; increases BDNF expression
- Phase II trials in Russia; limited Western data
- 300–600mcg intranasal daily
- Russian pharmaceutical approval; not FDA-approved
- Moderate evidence; nasal administration improves compliance